- Home
- KBDC vs GHRS Comparison
KBDC vs GHRS Comparison
Compare KBDC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KBDC | GHRS |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 892.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KBDC | GHRS |
|---|---|---|
| Price | $15.25 | $13.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $15.80 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 268.5K | 247.9K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $193.84 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.06 | $6.72 |
| 52 Week High | $17.99 | $20.50 |
Technical Indicators
Market Signals| Indicator | KBDC | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.00 | 41.50 |
| Support Level | $15.09 | $13.94 |
| Resistance Level | $15.42 | $15.00 |
| Average True Range (ATR) | 0.26 | 0.84 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 49.57 | 3.99 |
Price Performance
Historical ComparisonAbout KBDC Kayne Anderson BDC Inc.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.